Medical Genetics Service, Hospital de Clinicas, Porto Alegre, RS, Brazil.
Gene. 2013 Sep 10;526(2):150-4. doi: 10.1016/j.gene.2013.05.007. Epub 2013 May 21.
Hunter disease or mucopolysaccharidosis type II (MPS II) is an X-linked recessive lysosomal disorder caused by the deficit of the enzyme iduronate-2-sulfatase (IDS), involved in the catabolism of the glycosaminoglycans heparan and dermatan sulfate. Our aim was to search for molecular defects in the promoter region of the IDS gene in patients with previous biochemical diagnosis of MPS II and after we sequenced the whole IDS coding region and the exon/intron boundaries without detecting any pathogenic mutations. Screening of the promoter region of four patients detected in two of them a 178 bp deletion and in the other two a single nucleotide substitution 818 bp upstream of the coding region. The latter had never been described before in MPS II patients and it turned out to be a polymorphism. Our experience suggests that MPS II patients with no mutations detected in the IDS coding region should be screened in the promoter region of the gene. Findings will hopefully help to clarify the relationship between genotype and phenotype and will be useful for the correct molecular diagnosis of Hunter patients and the identification of female carriers, the latter particularly important for genetic counseling.
亨特病或黏多糖贮积症 II 型(MPS II)是一种 X 连锁隐性溶酶体疾病,由缺乏伊古氨酸-2-硫酸酯酶(IDS)引起,该酶参与硫酸乙酰肝素和硫酸皮肤素的糖胺聚糖代谢。我们的目的是在先前生化诊断为 MPS II 的患者中,在我们测序整个 IDS 编码区及其exon/intron 边界后,没有发现任何致病性突变的情况下,在 IDS 基因的启动子区域寻找分子缺陷。对四名患者的启动子区域进行筛查,在其中两名患者中发现了 178bp 的缺失,在另外两名患者中发现了 818bp 的编码区域上游的单个核苷酸取代。后者以前从未在 MPS II 患者中描述过,结果证明是一种多态性。我们的经验表明,在 IDS 编码区未发现突变的 MPS II 患者应在该基因的启动子区域进行筛查。研究结果有望有助于阐明基因型与表型之间的关系,并将有助于对亨特患者进行正确的分子诊断和识别女性携带者,后者对遗传咨询尤为重要。